0	14	Glucocorticoid	glucocorticoid	NN
15	23	receptor	receptor	NN
24	26	in	in	IN
27	35	patients	patient	NNS
36	40	with	with	IN
41	46	lupus	lupus	NN
47	56	nephritis	nephritis	NN
56	57	:	:	:
58	70	relationship	relationship	NN
71	78	between	between	IN
79	87	receptor	receptor	NN
88	94	levels	level	NNS
95	97	in	in	IN
98	109	mononuclear	mononuclear	JJ
110	120	leukocytes	leukocyte	NNS
121	124	and	and	CC
125	131	effect	effect	NN
132	134	of	of	IN
135	149	glucocorticoid	glucocorticoid	NN
150	157	therapy	therapy	NN
157	158	.	.	.

160	162	We	we	PRP
163	175	investigated	investigate	VBD
176	179	the	the	DT
180	188	clinical	clinical	JJ
189	201	significance	significance	NN
202	204	of	of	IN
205	219	glucocorticoid	glucocorticoid	NN
220	228	receptor	receptor	NN
229	242	determination	determination	NN
243	245	in	in	IN
246	248	20	20	CD
249	257	patients	patient	NNS
258	262	with	with	IN
263	271	systemic	systemic	JJ
272	277	lupus	lupus	NN
278	291	erythematosus	erythematosus	NN
292	293	(	(	(
293	296	SLE	sle	NN
296	297	)	)	)
298	301	who	who	WP
302	312	afterwards	afterwards	RB
313	322	developed	develop	VBD
323	332	nephrotic	nephrotic	JJ
333	341	syndrome	syndrome	NN
341	342	.	.	.

343	357	Glucocorticoid	glucocorticoid	NN
358	366	receptor	receptor	NN
367	381	concentrations	concentration	NNS
382	384	in	in	IN
385	396	mononuclear	mononuclear	JJ
397	407	leukocytes	leukocyte	NNS
408	409	(	(	(
409	412	MNL	MNL	NNP
412	413	)	)	)
414	416	in	in	IN
417	422	these	these	DT
423	431	patients	patient	NNS
432	436	were	be	VBD
437	447	comparable	comparable	JJ
448	452	with	with	IN
453	458	those	those	DT
459	461	in	in	IN
462	466	both	both	CC
467	472	other	other	JJ
473	481	patients	patient	NNS
482	486	with	with	IN
487	490	SLE	SLE	NNP
491	494	and	and	CC
495	502	healthy	healthy	JJ
503	510	persons	person	NNS
510	511	.	.	.

512	523	Improvement	Improvement	NNP
524	526	in	in	IN
527	534	urinary	urinary	JJ
535	542	protein	protein	NN
543	552	excretion	excretion	NN
553	556	and	and	CC
557	559	in	in	IN
560	567	disease	disease	NN
568	576	activity	activity	NN
576	577	,	,	,
578	583	which	which	WDT
584	587	was	be	VBD
588	594	scored	score	VBN
595	604	according	accord	VBG
605	607	to	to	TO
608	611	the	the	DT
612	615	SLE	SLE	NNP
616	623	Disease	Disease	NNP
624	632	Activity	Activity	NNP
633	638	Index	Index	NNP
639	645	system	system	NN
646	648	of	of	IN
649	652	the	the	DT
653	663	University	University	NNP
664	666	of	of	IN
667	674	Toronto	Toronto	NNP
674	675	,	,	,
676	683	closely	closely	RB
684	691	related	related	JJ
692	694	to	to	TO
695	698	the	the	DT
699	713	glucocorticoid	glucocorticoid	NN
714	722	receptor	receptor	NN
723	737	concentrations	concentration	NNS
738	740	in	in	IN
741	744	MNL	MNL	NNP
745	753	isolated	isolate	VBN
754	758	from	from	IN
759	762	the	the	DT
763	776	corresponding	corresponding	JJ
777	785	patients	patient	NNS
785	786	.	.	.

787	789	In	in	IN
790	797	summary	summary	NN
797	798	,	,	,
799	813	glucocorticoid	glucocorticoid	NN
814	822	receptor	receptor	NN
823	836	determination	determination	NN
837	839	in	in	IN
840	848	patients	patient	NNS
849	853	with	with	IN
854	859	lupus	lupus	NN
860	869	nephritis	nephritis	NN
870	873	may	may	MD
874	876	be	be	VB
877	878	a	a	DT
879	889	predictive	predictive	JJ
890	894	clue	clue	NN
895	898	for	for	IN
899	908	assessing	assess	VBG
909	923	responsiveness	responsiveness	NN
924	926	to	to	TO
927	941	glucocorticoid	glucocorticoid	NN
942	949	therapy	therapy	NN
949	950	.	.	.